In vivo最新文献

{"title":"Claudin 18.2 Expression in Gastric Tumors and Other Tumor Types With Gastric Epithelium-like Differentiation.","authors":"Moonsik Kim, Ha Young Woo, Jinhee Kim, An Na Seo","doi":"10.21873/invivo.13954","DOIUrl":"https://doi.org/10.21873/invivo.13954","url":null,"abstract":"<p><strong>Background/aim: </strong>Claudin 18.2 is an emerging biomarker for claudin 18.2-targeted therapy. We investigated claudin 18.2 expression in diverse tumor types.</p><p><strong>Patients and methods: </strong>We retrospectively analyzed 67 gastric tumors (61 surgically resected and six biopsy specimens) and 73 other tumor types (69 resected and four biopsy specimens), including those from the pancreas, hepatobiliary system, lung, ovary, uterine cervix, and others. Claudin 18.2 expression and positivity (≥75% of tumor cells showing moderate to strong membranous staining) were assessed using claudin 18 immunostaining (clone 43-14A).</p><p><strong>Results: </strong>Claudin 18.2 positivity was found in 47.8% (32/67) of gastric tumor samples. Epstein-Barr virus-associated gastric cancer showed a higher frequency of positivity (6/7, 85.7%), although not statistically significantly (<i>p</i>=0.216). Among gastric tumors from patients with lymph node or distant metastasis (n=20), four (20.0%) exhibited discrepancies in claudin 18.2 positivity between the primary and its metastasis. In other tumor types, claudin 18.2 positivity was more frequent in those with gastric epithelium-like differentiation, including pancreatic tumors (2/9, 22.2%), hepatobiliary carcinoma (2/8, 25.0%), invasive mucinous lung adenocarcinoma (4/5, 80.0%), and mucinous ovarian tumor (5/5, 100.0%) than in those with other histology (<i>p</i><0.001). Interestingly, pancreatic tumors, potential candidates for claudin 18.2-targeted therapy, often exhibited reduced or lack of claudin 18.2 expression in the invasive component.</p><p><strong>Conclusion: </strong>Overall, claudin 18.2 positivity occurred primarily in a significant proportion of gastric tumors and other tumors with gastric epithelium-like differentiation. Evaluating claudin 18.2 expression in all such tumors can benefit patients by guiding targeted therapy. Additionally, claudin 18.2 immunostaining serves as a lineage marker for gastric origin or gastric-like differentiation.</p>","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 3","pages":"1540-1553"},"PeriodicalIF":1.8,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12042001/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143985502","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association Between Early Recovery of Renal Function and Residual Renal Function After Robot-assisted Partial Nephrectomy.","authors":"Shunta Hori, Mitsuru Tomizawa, Kenta Onishi, Yosuke Morizawa, Daisuke Gotoh, Tomonori Nakahama, Yasushi Nakai, Makito Miyake, Tatsuo Yoneda, Nobumichi Tanaka, Kiyohide Fujimoto","doi":"10.21873/invivo.13955","DOIUrl":"https://doi.org/10.21873/invivo.13955","url":null,"abstract":"<p><strong>Background/aim: </strong>This study aimed to explore factors related to residual renal function in patients with small renal tumors treated with robot-assisted partial nephrectomy.</p><p><strong>Patients and methods: </strong>This retrospective study included 188 patients with two functioning kidneys who were diagnosed with localized renal tumors and underwent robot-assisted partial nephrectomy using the clamping technique. The residual renal function 12 months after the surgery was evaluated in two ways: >90% preservation of the estimated glomerular filtration rate and no stage progression of chronic kidney disease.</p><p><strong>Results: </strong>The median age, body mass index, and warm ischemic time were 68 years, 23.3 kg/m², and 19 min, respectively. Ten patients were diagnosed with positive surgical margins. Multivariate analysis revealed no significant preoperative factors, including renal function. Among surgical factors, warm ischemic time was an independent factor for chronic kidney disease progression, whereas it showed no significant association with the preservation of residual renal function (<i>p</i> =0.042 and p=0.14, respectively). Early recovery, defined as the difference in estimated glomerular filtration rate before and three months post-surgery, independently correlated with poor residual renal function preservation and chronic kidney disease progression (<i>p</i><0.0001 and <i>p</i><0.0001, respectively). Furthermore, no significant difference was observed in residual renal function recovery between warm ischemic time <25 and ≥25 min (<i>p</i>=0.58).</p><p><strong>Conclusion: </strong>Early recovery from residual renal function was crucial for preserving residual renal function and preventing chronic kidney disease progression after surgery. Understanding the factors influencing residual renal function preservation might lead to the optimization of treatment strategies in current clinical practice.</p>","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 3","pages":"1554-1566"},"PeriodicalIF":1.8,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12041977/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143977856","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of the Setup Accuracy of a Skin-markerless Positioning Using Surface-guided Radiotherapy in Accelerated Partial Breast Irradiation.","authors":"Ryohei Yamauchi, Fumihiro Tomita, Tomoyuki Masuda, Shinobu Akiyama, Nobue Uchida, Satoshi Ishikura","doi":"10.21873/invivo.13960","DOIUrl":"https://doi.org/10.21873/invivo.13960","url":null,"abstract":"<p><strong>Background/aim: </strong>Accelerated partial breast irradiation (APBI) is an alternative to whole-breast irradiation in early-stage breast cancer. This study evaluated the setup accuracy of a workflow without skin markers that uses surface-guided radiotherapy (SGRT) in conjunction with clip-based alignment in patients undergoing APBI.</p><p><strong>Patients and methods: </strong>This study recruited 35 patients who underwent APBI after breast-conserving surgery. Treatment plans were generated with 30 Gy in five fractions. During the treatment period, patients were positioned using AlignRT, intentionally omitting the skin marks. After the initial setup, the position was verified <i>via</i> daily kV images or cone-beam computed tomography, with matching surgical clips serving as the basis. Translational and rotational shifts were recorded, along with the monitoring-on time by AlignRT.</p><p><strong>Results: </strong>A total of 175 treatment fractions were analyzed. The mean±standard deviation (SD) residual setup error detected <i>via</i> image registration was 0.01±0.18, -0.09±0.22, and -0.04±0.19 cm in the vertical, longitudinal, and lateral axes, respectively. Setup accuracy within 5 mm in all axes was achieved in over 95% of the treatment fractions assessed. During the treatment period, 28% of patients (10 out of 35) maintained position deviations of less than 3 mm in the 3D vector direction. The mean±SD monitoring-on time was 603.3±214.1 s (range=349-1,353 s).</p><p><strong>Conclusion: </strong>The integration of surface-guided radiation therapy and clip alignment effectively achieved accurate and efficient patient positioning; this can serve as an alternative to traditional skin markers in the external beam APBI workflow.</p>","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 3","pages":"1598-1606"},"PeriodicalIF":1.8,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12041973/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144003642","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Immersive Virtual Reality for Reducing Intraoperative Pain: A Pilot Randomized Controlled Trial.","authors":"Teppei Kamada, Hironori Ohdaira, Ryosuke Nishie, Daisuke Yamagishi, Takashi Aida, Junji Takahashi, Eisaku Ito, Shunjin Ryu, Satoshi Narihiro, Reo Takizawa, Taigo Hata, Masashi Yoshida, Ken Eto, Makoto Sumi, Yutaka Suzuki","doi":"10.21873/invivo.13964","DOIUrl":"10.21873/invivo.13964","url":null,"abstract":"<p><strong>Background/aim: </strong>In this study, we aimed to evaluate the effect of virtual reality (VR) therapy on pain, anxiety, and other outcomes in patients with cancer undergoing central venous (CV) port placement.</p><p><strong>Patients and methods: </strong>We conducted a single-center randomized controlled trial with 10 adults with cancer undergoing CV port placement. Participants were randomized into the VR group (n=5), which received VR therapy with the Therapeia VR system (xCura), or the control group (n=5), which underwent conventional procedures. The primary and secondary outcomes included intraoperative pain, intraoperative and postoperative anxiety, blood loss, operative time, sensation of obstruction, and patient and surgeon satisfaction.</p><p><strong>Results: </strong>No significant differences were found between the VR and control groups regarding operative time, blood loss, preoperative anxiety, obstruction sensation, or surgeon satisfaction. However, compared with the control group, the VR group showed markedly lower intraoperative pain (<i>p</i>=0.03), intraoperative/postoperative anxiety (<i>p</i>=0.04), and higher patient satisfaction (<i>p</i>=0.03).</p><p><strong>Conclusion: </strong>The use of immersive VR therapy during CV port placement significantly reduced intraoperative pain and anxiety and enhanced patient satisfaction. These findings indicated that VR therapy may be an effective nonpharmacological adjunct for improving patient experience during invasive procedures.</p>","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 3","pages":"1638-1646"},"PeriodicalIF":1.8,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12041976/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144062373","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bone Metabolism-related Serum Biomarkers and Nutritional Markers for Bone Fractures in Living-donor Kidney Transplant Recipients.","authors":"Shunta Hori, Mitsuru Tomizawa, Kuniaki Inoue, Tatsuo Yoneda, Kenta Onishi, Yosuke Morizawa, Daisuke Gotoh, Yasushi Nakai, Makito Miyake, Kazumasa Torimoto, Nobumichi Tanaka, Kiyohide Fujimoto","doi":"10.21873/invivo.13949","DOIUrl":"https://doi.org/10.21873/invivo.13949","url":null,"abstract":"<p><strong>Background/aim: </strong>The clinical importance of fracture prevention in patients with end-stage renal disease is well-established. We investigated the roles of bone metabolism-related serum biomarkers and nutritional markers for fractures in Japanese living-donor kidney transplant recipients.</p><p><strong>Patients and methods: </strong>We included 204 consecutive patients who underwent kidney transplantation at Nara Medical University between 2003 and 2022 and retrospectively reviewed their medical charts. The cumulative incidence of fractures was investigated by focusing on bone metabolism-related serum biomarkers and nutritional markers, and related markers were explored.</p><p><strong>Results: </strong>The age at surgery in the fracture group was significantly higher than that in the no-fracture group (<i>p</i>=0.018). Patients with fractures had a significantly higher risk of mortality than those without fractures (<i>p</i>=0.0018); cardiovascular mortality was higher in the fracture group than in the non-fracture group (<i>p</i>=0.052). The cumulative incidence of fractures (median follow-up period, 98 months) was 4.6% at 1 year, 8.6% at 2 years, 12.3% at 3 years, and 15.5% at 5 years after transplant. Particularly, patients with a survival index <26.1 had a significantly higher risk of fracture (<i>p</i>=0.014). Serum intact parathyroid hormone level (a bone metabolism-related biomarker) and survival index (a nutritional marker) were independently related to fractures (<i>p</i>=0.046 and <i>p</i>=0.022, respectively).</p><p><strong>Conclusion: </strong>Serum intact parathyroid hormone level and the survival index may play important roles in determining the incidence of fractures in living donor kidney transplant recipients. Identifying patients at high risk of fractures and providing optimal intervention and education may contribute to improved and personalized management strategies.</p>","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 3","pages":"1492-1504"},"PeriodicalIF":1.8,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12041986/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143963298","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of DNA Aptamer Concentration on the Stability of PDA Nanoparticle-based Electrochemical Biosensor to Detect Glycated Albumin.","authors":"Ohnmar Zaw, Nang Noon Shean Aye, Paweena Tunakhun, Jureerut Daduang, Sakda Daduang, Pornsuda Maraming","doi":"10.21873/invivo.13945","DOIUrl":"https://doi.org/10.21873/invivo.13945","url":null,"abstract":"<p><strong>Background/aim: </strong>The glycated albumin (GA), a potential biomarker for monitoring diabetes mellitus, reflects short-term glycemia and is not influenced by conditions that falsely alter hemoglobin A1c (HbA1c) levels. This study presents a comprehensive evaluation of DNA aptamer-functionalized polydopamine nanoparticles (PDA NPs) for developing a stable biosensor targeting GA.</p><p><strong>Materials and methods: </strong>DNA aptamers, conjugated to PDA NPs at varying aptamer concentrations (0.05, 0.5, and 5 μM), were systematically analyzed to understand their impact on the morphological, electrochemical behavior, and stable responses of the biosensor.</p><p><strong>Results: </strong>Morphological assessments using transmission electron microscopy, scanning electron microscopy, and atomic force microscopy confirmed the stability of PDA NPs after conjugation with aptamers. Electrochemical characterization demonstrated enhanced electron transfer efficiency at an optimal aptamer concentration (0.5 μM) for GA detection while stability testing over 30 days indicated sustained sensor functionality.</p><p><strong>Conclusion: </strong>The PDA-0.5 μM aptamer conjugations balance structural integrity, and stability, emphasizing the importance of aptamer concentration optimization for practical biosensor applications.</p>","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 3","pages":"1440-1452"},"PeriodicalIF":1.8,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12041966/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144014219","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Inhibitory Effect of Clopidogrel, a P2Y₁₂ Receptor Antagonist, on Hematogenic Metastasis in B16-BL6 Mouse Melanoma Cells.","authors":"Noriko Yoshikawa, Mingyu Xia, Kazuki Nakamura","doi":"10.21873/invivo.13936","DOIUrl":"https://doi.org/10.21873/invivo.13936","url":null,"abstract":"<p><strong>Background/aim: </strong>The complex interactions between circulating platelets and tumor cells play important roles in tumor metastasis. Tumor cells can activate platelets by releasing mediators such as adenosine diphosphate (ADP). Treatments with anticoagulants have been shown to attenuate tumor metastasis. However, the role of ADP receptor P2Y₁₂ in tumor cell metastasis has not been fully clarified.</p><p><strong>Materials and methods: </strong>In this study, highly metastatic B16-BL6 mouse melanoma cells were injected into the tail vein of mice as a model of hematogenic tumor metastasis to investigate the effects of P2Y₁₂ antagonist clopidogrel on tumor metastasis.</p><p><strong>Results: </strong>A high dose (25 mg/kg) of clopidogrel weakly but significantly inhibited lung metastasis and increased both the time to hemostasis and blood loss in the tail tip-excision mouse model.</p><p><strong>Conclusion: </strong>Although it is necessary to consider increased bleeding as a side-effect, clopidogrel may be an effective antimetastatic drug.</p>","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 3","pages":"1325-1330"},"PeriodicalIF":1.8,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12041989/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144005303","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cancer-induced Pain Is Associated With Poor Overall Survival of Urothelial Carcinoma Patients Treated With Enfortumab Vedotin.","authors":"Mamoru Hashimoto, Ken Fukiage, Kosei Taniguchi, Takafumi Minami, Takafumi Yanagisawa, Wataru Fukuokaya, Ryoichi Maenosono, Yuki Yoshikawa, Takuya Tsujino, Masanobu Saruta, Kiyoshi Takahara, Yosuke Hirasawa, Takeshi Hashimoto, Yoshio Ohno, Takahiro Kimura, Ryoichi Shiroki, Kazutoshi Fujita","doi":"10.21873/invivo.13953","DOIUrl":"https://doi.org/10.21873/invivo.13953","url":null,"abstract":"<p><strong>Background/aim: </strong>Cancer-induced pain (CIP) exacerbates patient's quality of life. However, it is unknown whether CIP is associated with survival in urothelial carcinoma (UC) patients treated with enfortumab vedotin (EV). This study retrospectively investigated the prognostic significance of CIP in EV-treated UC patients.</p><p><strong>Patients and methods: </strong>We analyzed clinical data from patients with locally advanced or metastatic UC who received EV treatment, assessing various factors such as age, metastasis site, ECOG Performance Status (PS), and CIP status prior to treatment. CIP was determined based on clinical records cancer-related pain or the use of analgesics for pain management.</p><p><strong>Results: </strong>A total of 114 patients (78 males and 36 females) were included in the study. The group with CIP included significantly higher number of patients with bone metastasis. Progression-free survival of the patients with CIP was not significantly different from those without CIP. However, the patients with CIP showed worse overall survival (OS) than those without CIP. Cox proportional regression analysis showed that CIP, liver metastasis, and ECOG PS were significant predictors of poorer OS.</p><p><strong>Conclusion: </strong>CIP before the treatment of EV was a significant predictor of reduced OS in patients with UC. Early management of CIP or initiation of EV therapy before CIP development may improve survival outcomes.</p>","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 3","pages":"1533-1539"},"PeriodicalIF":1.8,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12041981/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143998660","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"HT1080 Human Fibrosarcoma Cells Selected for Super-eribulin Resistance <i>In Vitro</i> Become More Malignant and Are Arrested Synergistically by Methionine Restriction in Combination With Eribulin in Nude Mice.","authors":"Sei Morinaga, Kohei Mizuta, Byung Mo Kang, Qinghong Han, Michael Bouvet, Norio Yamamoto, Katsuhiro Hayashi, Hiroaki Kimura, Shinji Miwa, Kentaro Igarashi, Takashi Higuchi, Hiroyuki Tsuchiya, Satoru Demura, Robert M Hoffman","doi":"10.21873/invivo.13931","DOIUrl":"https://doi.org/10.21873/invivo.13931","url":null,"abstract":"<p><strong>Background/aim: </strong>Eribulin is a microtubule inhibitor used in the treatment of various malignancies, including soft-tissue sarcoma. However, the development of eribulin resistance is a recalcitrant clinical problem. The present study demonstrates that super eribulin-resistant HT1080 human fibrosarcoma cells become highly malignant but can be eradicated synergistically by the combination of eribulin and methionine restriction in nude mice.</p><p><strong>Materials and methods: </strong>The cell viability of parental HT1080 cells and super eribulin-resistant HT1080 was determined following eribulin treatment using the WST-8 reagent. <i>In vitro</i> invasion assays, comprising wound-healing of cell monolayers, were performed to determine the degree of malignancy. Tumor growth to determine malignancy and tumor-growth sensitivity to eribulin, or a methionine-restricted diet, or their combination were analyzed in athymic nude mice.</p><p><strong>Results: </strong>The IC₅₀ of eribulin for parental HT1080 cells was 0.15 nM, whereas for super eribulin-resistant HT1080 cells, the IC₅₀ of eribulin was 18 nM, a 120-fold increase. Super eribulin-resistant HT1080 cells had a more rapid wound-healing closure rate <i>in vitro</i> than their parental HT1080 cells, indicating increased malignancy. Similarly, <i>in vivo</i>, untreated super eribulin-resistant HT1080 tumors grew faster than parental HT1080 tumors, confirming their high malignancy. The combination of a methionine-restricted diet and eribulin synergistically arrested super eribulin-resistant HT1080 tumors. Methionine restriction sensitized these highly resistant and malignant cells to eribulin.</p><p><strong>Conclusion: </strong>Methionine restriction combined with eribulin represents a promising strategy to effectively treat eribulin-resistant high-malignancy fibrosarcoma, that can be immediately applied to the clinic.</p>","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 3","pages":"1275-1282"},"PeriodicalIF":1.8,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12041979/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143991850","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic Role of Prostate-specific Antigen Isoforms and Their Early Kinetics in Patients With Metastatic Castration-resistant Prostate Cancer Receiving New Generation Androgen Receptor Targeted Agents.","authors":"Ondřej Fiala, Petr Hošek, Hana Korunková, Michaela Tkadlecová, Milan Hora, Dominika Šiková, Petr Stránský, Jindřich Fínek, Radek Kučera, Jindra Windrichová, Ondřej Topolčan","doi":"10.21873/invivo.13889","DOIUrl":"10.21873/invivo.13889","url":null,"abstract":"<p><strong>Background/aim: </strong>New generation androgen receptor-targeting agents (ARTA) have been in the spotlight for their efficacy in metastatic castration-resistant prostate cancer (mCRPC). Prostate-specific antigen (PSA) represents one of the most commonly used serum cancer biomarkers worldwide. The present retrospective study focused on the prognostic role of serum PSA isoforms and their early dynamics in mCRPC patients treated with abiraterone acetate (ABI) or enzalutamide (ENZ).</p><p><strong>Patients and methods: </strong>The association between outcomes of 334 mCRPC patients treated with ABI or ENZ and the levels of serum total PSA (tPSA), free PSA (fPSA), [-2]proPSA and the Prostate Health Index (PHI) at baseline and one month after treatment initiation was analyzed retrospectively.</p><p><strong>Results: </strong>In the multivariable Cox proportional hazards models, baseline tPSA>50 μg/l (<i>p</i><0.001), and [-2]proPSA>300 ng/l (<i>p</i>=0.017) remained independent significant factors associated with inferior OS, while baseline fPSA>1.75 μg/l (<i>p</i>=0.050) and Δ [-2]proPSA >-50% approached statistical significance (<i>p</i>=0.062). The results of ROC analyses assessing the ability of baseline tPSA, fPSA, and [-2]proPSA to predict mortality within two years showed area under the curve (AUC) values of 0.709, 0.685, and 0.740, respectively. Among the subgroup with baseline tPSA≤20.0 μg/l, the results of ROC analyses for baseline tPSA, fPSA and [-2]proPSA showed AUC values of 0.441, 0.682, and 0.688, respectively.</p><p><strong>Conclusion: </strong>Our results suggest a significant correlation between pretreatment serum levels of tPSA and [-2]proPSA with OS in mCRPC patients receiving ARTA.</p>","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 2","pages":"859-869"},"PeriodicalIF":1.8,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11884487/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143515538","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}